Success in First Real-World Case of Relatlimab Combo for Treatment of Conjunctival Melanoma
Source: Doc Wire News, November 2024
With recent interest in immunotherapy on the rise, researchers led by Mirona Attrash treated an older patient presenting with invasive conjunctival melanoma who elected to bypass surgery with the combination of relatlimab-nivolumab (anti-PD-L1/anti-LAG3 inhibitors).
This is the first reported real-world case of a patient successfully treated with relatlimab-nivolumab for conjunctival melanoma, displaying the combination’s high efficacy in treating the complex disease. Up until this point, the combination has been used to treat cutaneous melanoma based on the data from the successful RELATIVITY-047 trial.
RELATIVITY-047
In the global, phase 2-3, double-blind, randomized trial, of the 714 participants with previously untreated unresectable cutaneous melanoma, 359 received single-agent nivolumab and 355 received relatlimab-nivolumab.